Durable Efficacy of Certolizumab Pegol Dosed at 400 mg Every Two Weeks Over 128 Weeks in Patients with Plaque Psoriasis Enrolled in Three Phase 3 Trials (CIMPASI-1, CIMPASI-2 and CIMPACT)

Main Article Content

K Gordon
R B Warren
A B Gottlieb
A Blauvelt
D Thaçi
Y Poulin
M Boehnlein
F Brock
C Arendt
K Reich

Keywords

Psoriasis, Biologics, Certolizumab, efficacy

Abstract

Abstract not available.

References

1. Gottlieb A.B. et al. JAAD 2018;79:302–14.e6;

2. Lebwohl M. et al. JAAD 2018;79:266–76.e5.